Literature DB >> 21466774

[Which analgesic after dextropropoxyphene withdrawal? A survey in a sample of general practitioners in southwest of France].

Serge Bismuth1, Eng Laing Leng, Stéphane Oustric, Jean-Louis Montastruc, Maryse Lapeyre-Mestre.   

Abstract

Following the announcement of the future withdrawal in Europe of drugs containing dextropropoxyphene-paracetamol (DXP-P), we performed a postal survey in a randomly selected sample of 350 general practitioners (GP) from the Midi-Pyrénées area (2.6 million inhabitants) in order to investigate which drug (s) they are willing to prescribe in anticipation of the announced withdrawal. Most of GP prescribed DXP-P in acute and chronic pain. In acute pain, GP would switch to codeine-paracetamol (59.1%) or tramadol alone or associated with paracetamol (79%), whereas they would switch to high dose paracetamol (54.7%) and tramadol alone or associated with paracetamol (74.6%) in chronic pain. Switching to other level 2 analgesic drugs after the withdrawal of dextropropoxyphene should be closely monitored because the safety profile of other drugs.
© 2011 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466774     DOI: 10.2515/therapie/2011004

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  5 in total

1.  Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain.

Authors:  Laurent Becquemont; Tiba Delespierre; Bernard Bauduceau; Linda Benattar-Zibi; Gilles Berrut; Emmanuelle Corruble; Nicolas Danchin; Geneviève Derumeaux; Jean Doucet; Bruno Falissard; Francoise Forette; Olivier Hanon; Florence Pasquier; Michel Pinget; Rissane Ourabah; Sophie Bucher; Aida Lazkani; Celine Piedvache; Philippe Bertin
Journal:  Eur J Clin Pharmacol       Date:  2014-07-29       Impact factor: 2.953

2.  Preventability of adverse effects of analgesics: analysis of spontaneous reports.

Authors:  Irina Cazacu; Ghada Miremont-Salamé; Cristina Mogosan; Annie Fourrier-Réglat; Felicia Loghin; Françoise Haramburu
Journal:  Eur J Clin Pharmacol       Date:  2015-03-05       Impact factor: 2.953

3.  Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.

Authors:  Cécile Pageot; Julien Bezin; Andy Smith; Mickael Arnaud; Francesco Salvo; Françoise Haramburu; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

4.  Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.

Authors:  Antoine Pariente; Yohann Mansiaux; Ana Jarné; Francesco Salvo; Cécile Pageot; Julien Bezin; Andy Smith; Bernard Bégaud
Journal:  Eur J Clin Pharmacol       Date:  2017-09-02       Impact factor: 2.953

5.  Use of analgesics in France, following dextropropoxyphene withdrawal.

Authors:  E Van Ganse; M Belhassen; M Ginoux; E Chrétien; C Cornu; C Ecoffey; F Aubrun
Journal:  BMC Health Serv Res       Date:  2018-04-02       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.